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Ral GTPases have been implicated as critical 
drivers of cell growth and metastasis in numerous 
Ras-driven cancers. We have previously reported 
stapled peptides, based on the Ral effector 
RLIP76, that can disrupt Ral signaling. Stapled 
peptides are short peptides that are locked into 
their bioactive form using a synthetic brace. Here, 
using an affinity maturation of the RLIP76 Ral-
binding domain, we identified several sequence 
substitutions that together improve binding to Ral 
proteins by more than 20-fold. Hits from the 
selection were rigorously analyzed to determine 
the contributions of individual residues and two 
1.5 Å co-crystal structures of the tightest-binding 
mutants in complex with RalB revealed key 
interactions. Insights gained from this maturation 
were used to design second-generation stapled 
peptides based on RLIP76 that exhibited vastly 
improved selectivity for Ral GTPases when 
compared to the first-generation lead peptide. The 
binding of second-generation peptides to Ral 
proteins was quantified and the binding site of the 
lead peptide on RalB was determined by NMR. 
Stapled peptides successfully competed with 
multiple Ral-effector interactions in cellular 
lysates.  Our findings demonstrate how 
manipulation of a native binding partner can assist 
in the rational design of stapled peptide inhibitors 




Ras proteins (H-Ras, N-Ras and K-Ras) are well-
known as the most commonly mutated 
oncoproteins in human cancer, with activating 
mutations found in approximately 20% of cancers 
and with higher incidences in pancreatic (88%), 
colorectal (55%) and lung cancers (33%) (1). 
These small GTPases exist in two distinct 
conformations; an inactive GDP-bound form, and 
an active GTP-bound form in which they can bind  
 
and signal through downstream effector proteins. 
Through this mechanism they have the ability to  
act as molecular switches. Ras signalling is 
‘switched on’ by proteins known as Guanine 
Exchange Factors (GEFs) and ‘switched off’ by 
GTPase Activating Proteins (GAPs, reviewed in 
2).  
 
Most Ras mutations found in cancer render the 
protein constitutively active, in the GTP-bound 
state. This leads to deregulated signalling through 
downstream effector pathways, resulting in 
uncontrolled cell growth and proliferation. Due to 
the prevalence of their activation in cancer, Ras 
proteins have been the subject of intense 
therapeutic targeting for the past four decades but, 
until recently, the lack of compounds to target Ras 
proteins directly meant that they were considered 
‘undruggable’ (for reviews see 3, 4). Several 
features of Ras proteins made them difficult 
targets: for instance, Ras proteins interact with 
their downstream effectors via protein-protein 
interactions (PPIs), which utilize large shallow 
surfaces that are often not amenable to targeting 
with small molecules. The nucleotide binding site 
on Ras, which would be an obvious point for small 
molecule intervention, has not been a viable target 
due to the high intracellular concentrations of GTP 
and a picomolar binding affinity of the nucleotide. 
Early attempts to block the post-translational 
processing of Ras, which is required for membrane 
association and subsequent activity, proved 
unsuccessful due to compensatory processing by 
an alternative mechanism (5, 6). There has 
however been recent success in the direct 
inhibition of the K-Ras G12C mutant commonly 
found in lung cancers: Shokat and colleagues 
identified a binding pocket proximal to cysteine 12 
that could be exploited to develop covalent 
inhibitors targeting this reactive residue (7). 
Several pharmaceutical companies have since 
reported their own candidates utilizing this 
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approach that are currently being tested in the 
clinic (8, 9). 
 
Difficulties in targeting Ras directly have resulted 
in considerable attempts to target effector 
pathways downstream of Ras. Of these, the Raf, 
PI3Kinase and RalGDS-Ral pathways are the best 
characterized and indeed many Raf and PI3K 
pathway inhibitors exist in the clinic (10, 11). 
These inhibitors can be used to treat certain 
cancers but feedback mechanisms leading to the 
activation of other effector pathways and a narrow 
therapeutic window have meant that their efficacy 
in Ras-mutant cancers is limited (12). 
Combination trials to assess the efficacy of 
blocking components from both pathways are 
currently underway (13–16), however preliminary 
results have suggested that these combinations are 
too toxic (17, 18).  
 
The third effector pathway downstream of Ras, the 
RalGDS-Ral pathway, has not yet been 
successfully targeted therapeutically despite 
growing evidence implicating this pathway as a 
critical mediator of survival in several Ras-mutant 
cancers, including pancreatic, colorectal, bladder 
and melanoma (19). Upon association with and 
activation by Ras·GTP, RalGDS activates the Ral 
(Ras-like) small GTPases, RalA and RalB. These 
are 206 amino acid proteins with 82% overall 
sequence identity and 100% identity in their 
effector binding regions. The Ral GTPases share a 
panel of effectors including RLIP76 (also called 
RalBP1), members of the exocyst complex (Sec5 
and Exo84) and the transcription factor ZONAB. 
Despite their high degree of similarity, the Ral 
proteins exhibit divergent and contrasting roles in 
signalling and therefore in cancer development 
(20). These differences are partly brought about by 
their flexible C-terminal hypervariable regions, 
which are the sites of lipidation and other post-
translational modifications and dictate the site of 
membrane interaction, resulting in differential 
subcellular localization of RalA and RalB (21).  
 
Early evidence of the critical role of Ral proteins 
in Ras-driven cancer came from Counter et al. 
who demonstrated that activation of the RalGDS-
Ral signalling pathway alone, and not Raf or 
PI3Kinase, was potent in transforming human 
cells (22). Constitutively activated RalA has been 
shown to be required for anchorage-independent 
growth of cancer cells (23–25), while RalB plays a 
role in invasion, metastasis (26) and the avoidance 
of apoptosis in tumour cells (27, 28).  However, 
proliferation of non-cancerous cells is unaffected 
by RalB activity (24). Inhibition of Ral-effector 
interactions can alleviate these effects as 
overexpression of a minimal Ral-binding domain 
(RBD) from RLIP76, which competes for effector 
binding, reduced anchorage-independent growth 
(24).  
 
The Ral proteins share the same structural fold as 
Ras proteins and are therefore expected to be 
equally challenging to target using small 
molecules. However, several early studies 
managed to identify small molecule inhibitors of 
the Ral GTPases. Yan et al. used in silico 
screening to identify small molecule inhibitors 
targeting a previously unidentified shallow 
binding pocket in the GDP-bound form of Ral, 
thereby stabilizing the inactive form and 
preventing Ral activation (29). Covalent inhibitors 
of Ral proteins have also been investigated: 
Meroueh and colleagues recently reported an 
inhibitor that was able to modify tyrosine 82 on 
Ral and subsequently inhibited GEF-mediated 
activation (30).  
 
Stapled peptides have emerged in recent years as 
promising therapeutic tools for targeting PPIs 
mediated by α-helices. The technique, developed 
by Verdine et al., involves the introduction of 
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unnatural olefin-bearing amino acids at i, i + 4/7 
positions, which are covalently linked by Grubbs’ 
ring closing metathesis (31). These chemical 
staples can induce and stabilize a helical structure 
and also impart other beneficial properties 
including cell penetration, increased proteolytic 
stability and improved binding affinity (31, 32). 
This approach has been successfully applied to 
target several small GTPases (reviewed in 33).  
 
We have previously reported the use of stapled 
peptides to inhibit Ral-effector interactions (34). 
Our solution structure of the Ral-binding domain 
(RBD) of RLIP76 in complex with RalB revealed 
that the interaction is mediated by a well-
structured coiled-coil domain in which more than 
80% of the interactions with Ral are mediated by 
the C-terminal α2 helix (35). As several effectors 
share a common binding site on Ral (36), we 
postulated that a peptide based on the RLIP76 
RBD would be able to inhibit multiple Ral-
effector interactions. We produced a series of 
stapled peptides spanning the RLIP76 RBD in 
which several staple lengths and positions were 
assessed (34). This work led to the identification 
of a stapled peptide based on the α2 helix of the 
RLIP76 RBD which was able to inhibit multiple 
Ral-effector interactions, enter cells and inhibit 
autophagy, a RalB-dependent process. The peptide 
was selective for active RalB over the closely 
related GTPase R-Ras. 
 
Here, we have used the RLIP76 RBD as a tool to 
guide the design of second-generation stapled 
peptides targeting the Ral GTPases. A CIS display 
selection using the RLIP76 RBD was performed to 
identify modified sequences with improved 
affinity for Ral proteins. These sequence 
alterations improved the affinity of stapled 
peptides based on the RLIP76 RBD in a similar 
manner. Investigations using the stapled peptide 
identified in previous work revealed issues relating 
to poor solubility and non-specific binding which 
have been addressed here, resulting in the 
development of stapled peptides with vastly 
improved solubility and selectivity for the active 





CIS display maturation of the RLIP76 RBD 
A series of CIS display selections (37) were 
carried out to identify potential sequence changes 
within our lead peptide sequence which could 
improve affinity for Ral proteins (Figure 1A). In 
CIS display, the variant library is fused to a gene 
encoding RepA, which captures the DNA from 
which it was translated upon recognition of a cis 
element, coupling the genetic material to the 
library. Up to 1014 sequences can be assessed by 
this method. As the unnatural amino acids utilized 
in the lead stapled peptide could not be included in 
an in vitro selection by conventional methods, the 
RLIP76 RBD (residues 393-446) was used as a 
model for peptide binding. During the selections, 
only residues that were contained in the lead 
peptide and were proximal to the Ral binding 
interface were permitted to alter (Figure 1B). 
Trp430 was retained as this residue was known to 
be critical for Ral binding (36). Biotinylated RalA 
and RalB were immobilized in separate selections 
to allow for the identification of sequences that 
discriminated between the two proteins. After four 
rounds of biopanning, enrichment of binding 
sequences was relatively low compared to similar 
selections (38). This phenomenon may indicate 
that the parent sequence has already achieved 
close to an evolutionary maximum binding 
capacity using proteinogenic amino acids. The 
sequences obtained were largely similar between 
selections involving RalA and RalB, reflecting the 
high sequence identity of these proteins. Three 
consensus sequences were identified across 
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multiple selections (Figure 1C) and represented 
the most enriched sequences from the selections. 
 
Biophysical analysis of CIS display sequences 
 
We reasoned that, while the consensus sequences 
represented an amalgamation of sequences, subtle 
residue co-operation within individual selected 
sequences might be required for high affinity 
binding. Therefore, a selection of individual 
sequences that appeared with the highest 
frequency for each of the three major clusters were 
produced recombinantly in E. coli to quantify their 
binding to Ral proteins. Sequences containing the 
K440P mutation (Cluster 3, Figure 1C) could not 
be produced due to protein precipitation during 
purification: it is likely that the helix-breaking Pro 
residue disrupts the structure of the protein leading 
to instability. The consensus sequence lacking the 
K440P substitution 
(E426L/E427T/Q433T/R434L/T437R) was 
produced as a His-tagged construct but did not 
bind to RalA in direct scintillation proximity 
assays (SPAs) (Figure S1). 
 
Affinities of the sequences for Ral proteins were 
measured in competition SPAs (Figure 2 and 
Table 1). Three out of six sequences tested bound 
more tightly than the wild-type RLIP76 RBD: all 
of these sequences were based on Cluster 1 
(Figure 1C) and the tightest binding sequences 
(HLR and SMLR) gave at least a 20-fold 
improvement in binding to both RalA and RalB. 
The sequences resembling Cluster 2 (Figure 1C, 
WDASQSR, WNASELR and WDASTAY) all 
bound with lower affinity than the wild-type 
RLIP76 RBD. Competition SPA experiments 
however only assess binding at the same site as the 
immobilized effector and it was possible that the 
sequences selected as Ral-binders in the CIS 
display selections occupied an alternative site on 
the Ral proteins. To ensure this was not the case, 
the WDASQSR mutant was produced as a His-
tagged construct and direct binding was assessed 
by SPA, however the protein did not bind to RalA 
(Figure S2), and circular dichroism experiments 
revealed that the coiled-coil structure of this 
mutant was disrupted (Figure S3). 
 
Co-crystal structures of mutant RBD 
complexes 
 
To investigate the mechanism(s) driving the 
improved binding of the mutants to the Ral 
proteins, we set out to obtain structural data on the 
complexes. We obtained high quality crystals for 
both the RalB/RLIP76 RBD HLR and SMLR 
mutant complexes, which diffracted to 1.5 Å 
resolution (Figure 3A and Table 2). The two 
structures were highly similar with an RMSD less 
than 0.1 Å and all interactions formed with Ral 
proteins were identical, suggesting that the 
E427H/S and R429M mutations were not 
important for binding.  
 
To delineate the thermodynamic contribution of 
the individual mutations in the HLR variant, 
constructs lacking each one of the changes were 
prepared and the binding of the HLR triple mutant 
and the three double mutants to RalB was assessed 
by ITC (Figure 4 and Table 3). The affinity of the 
wild-type RLIP76 RBD for RalB measured by 
ITC was 2.7 μM, in agreement with the previously 
reported value of 1.9 μM (34). The binding 
affinities measured by ITC differ from those 
measured by SPA competitions (approximately 
10-fold for the wild-type RBD), therefore only 
comparisons of values within a given technique 
have been made.  
 
As we have found previously, the interaction 
between RalB and the wild-type RLIP76 RBD was 
driven by a favourable enthalpic term (ΔH) which 
outweighs the entropic cost of binding (ΔS) (34). 
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The HLR mutant increased the binding to RalB 
28-fold, which is broadly similar to the 
improvements seen by SPA. The binding of the 
three double mutants revealed that the 
improvement in affinity was only observed when 
the Q433L mutation was present.  A variant 
harbouring the single Q433L mutation was 
produced and bound with a similar affinity to the 
HLR triple mutant, indicating that the Q433L 
mutation alone was sufficient to increase the 
affinity for RalB by 25-fold.  
 
The mutant RBD structures show that the 
sidechain of Leu433 contributes to a hydrophobic 
network of interactions involving several Ral 
residues (Ala48, Leu67, Tyr82) and Trp430 of 
RLIP76 (Figure 3B, middle panels). In the wild-
type RBD complex, Gln433 points out to the 
solvent, leaving a space at the edge of the 
hydrophobic pocket where Trp430 is buried in an 
interaction known to be essential for the binding 
affinity. When the Gln is replaced by Leu, the 
sidechain shifts towards the pocket and fills this 
space.  
 
Despite the obvious hydrophobic interactions that 
Leu433 makes in the complex, the ITC data 
showed that when RalB binds the Q433L mutant, 
the improved affinity compared to the wild-type 
RBD is due to a 2-fold increase in the favourable 
enthalpic contribution. Furthermore, the entropic 
cost of binding for the Q433L mutant was 3-4 fold 
greater than for the wild-type RBD, even though 
hydrophobic-driven interactions are usually 
characterized by a favourable entropic change. 
This suggests that the Q433L mutation in the RBD 
has a more nuanced effect on binding than simply 
contributing to the hydrophobic pocket around 
Trp430, perhaps by altering the presentation of 
other RBD residues.   
 
Lys440 forms a hydrogen bond with RalB Asp49 
in the wild-type complex (Figure 3B, bottom 
panels) and this interaction has been shown to be 
critical for binding to Ral, as alanine replacement 
reduced the affinity 10-fold (36). Replacement 
with arginine in the HLR and SMLR mutants 
allows this hydrogen bond to be maintained while 
an additional hydrogen bond with the backbone 
carbonyl of RalB Ala48 is gained. However, the 
K440R mutation only exerts a minimal 
improvement in binding of the RBD to Ral 
proteins, as evidenced by comparison of the 
E427H/Q433L (HL) double mutant with the 
E427H/Q433L/K440R (HLR) triple mutant, which 
bind with similar affinities (Figure 4 and Table 3).  
 
The replacement of Glu427 with histidine or 
serine breaks a salt bridge formed with RalB 
without forming any new interactions (Figure 3B, 
top panels) and ITC data demonstrated that this 
substitution did not improve binding to Ral 
proteins (Figure 4 and Table 3). Analysis of the 
sequences in Cluster 3 showed that the 
Q433L/K440R substitutions appeared together 
with high frequency, while position 427 was 
replaced by a range of amino acids. These 
observations, taken together, suggest that the 
conserved substitutions Q433L and K440R are the 
driving force for higher affinity binding.  
 
Second-generation stapled peptides 
  
We aimed to use the insights gained from the CIS 
display selections to improve the affinity of the 
first-generation stapled peptides targeting the Ral 
GTPases. In previous work we investigated a 
range of staple positions for peptides comprising 
residues 423-446 of the RLIP76 RBD (the α2 
helix) and found that a staple bridging residues 
424-428 produced the tightest binder, termed SP1 
(34). This lead peptide bound to RalA and RalB 
with Kd values of 14 and 5 μM, respectively, and 
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showed some selectivity for the Ral GTPases, 
binding more weakly to the related GTPase R-Ras 
with a Kd of 30 μM. Using a selection of the top 
hits identified in the CIS selection, we generated a 
series of peptides based on residues 423-446 of the 
RLIP76 RBD with the same staple position as the 
lead peptide (SP1). 
 
Peptides corresponding to the wild-type a2 
sequence (SP1) and those with the HLR sequence 
were compared for their binding to a panel of 
small GTPases using fluorescence polarization. 
This investigation into the specificity of the lead 
peptide, SP1, revealed issues with poor solubility 
and non-specific binding to several other small 
GTPases (see Figure S4 and Table S1), 
particularly RhoA: this non-specific binding was 
tighter in the HLR peptides. The peptides have a 
hydrophobic back face with exposed residues that 
would be buried within the coiled-coil interface in 
the RBD and the all-hydrocarbon staple further 
increases this hydrophobic surface. We reasoned 
that if the solubility profile of the peptides could 
be improved, this could increase the specificity. 
We hypothesized that the hydrophobic residues on 
the back face of the peptide could be replaced 
without negatively impacting binding affinity for 
Ral proteins and chose to substitute these with 
charged residues (glutamate and lysine), which 
would decrease hydrophobicity and 
simultaneously create two i, i + 4 salt bridges to 
help stabilise the helical structure of the peptides 
(Figure 5) (39). The resulting peptides were 
readily soluble in aqueous solution. 
 
The affinities of the soluble peptides for RalA 
were defined in competition SPAs by measuring 
their ability to compete with the RLIP76 RBD 
(Figure 6A and Table 4). The peptides containing 
single or triple mutations identified from the CIS 
display selection, modified to contain the 
solubilizing residues (designated HLR-sol and L-
sol), both bound with a Kd of approximately 3 μM, 
which was a 16-fold improvement on the ‘wild-
type’ sequence containing the same solubilizing 
mutations (wt-sol, Kd RalA = 49 μM). This 
demonstrates that the sequences identified using 
the RLIP76 RBD could be directly translated to 
produce peptide sequences with improved affinity 
for the Ral GTPases. Meanwhile, a peptide in 
which the critical tryptophan residue had been 
changed to alanine (W430A-sol), designed as a 
negative control peptide, showed very weak 
binding to RalA.  
 
These data demonstrate that the HLR-sol and L-
sol peptides are competitive with the RLIP76 RBD 
for binding to Ral proteins. We predicted that the 
peptides would also be able to inhibit other Ral-
effector interactions, therefore we tested the 
peptides in competition with the Sec5 RBD and 
found that they fully competed with Sec5 for 
binding to RalA (Figure 6B and Table 4). The Kd 
values of 1.7 and 1.8 μM for HLR-sol and L-sol 
binding to RalA respectively, agree with those 
measured by competition with the RLIP76 RBD.  
 
Direct binding fluorescence polarization assays 
were then used to assess selectivity of the peptides 
for Ral proteins over other small GTPases (Figure 
6C and D, Table 4). K-Ras was chosen as the Ras 
proteins are closely related to the Ral proteins, 
sharing more than 50% sequence identity, while 
Rac1 and RhoA were chosen as representatives of 
the Rho family of small GTPases. The HLR-sol 
and L-sol peptides bound to RalA and RalB with 
Kd values between 17 and 24 μM and showed no 
off-target binding to the other GTPases tested, 
demonstrating that the peptide selectivity is 
dramatically improved with the inclusion of the 
solubilizing mutations. The non-solubilized 
peptides bound to the other GTPases with 
affinities that were similar to those of the Ral 
proteins. The solubilized peptides showed no 
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binding to the no-Ral GTPases at concentrations 
up to 100 μM, indicating that any binding to the 
other GTPases was at least an order of magnitude 
lower in affinity than that of the Ral proteins. 
As our ultimate aim was to disrupt Ral-effector 
interactions for therapeutic purposes, it was highly 
desirable that the peptides were also selective for 
the active form of the Ral GTPases. The peptides 
demonstrated very little binding to RalA·GDP and 
are therefore selective for the active, GTP-bound 
form of Ral (Figure 6E and F, Table 4). These data 
also suggest that the peptides are binding at the 
nucleotide-sensitive switch regions, which are the 
known binding sites for most Ral effectors and 
regulatory proteins. This is in agreement with the 
peptides’ ability to compete with effector proteins, 
which also bind to the switch regions. 
 
Mapping the peptide binding site by NMR 
 
The binding site of the HLR-sol peptide was next 
investigated using chemical shift mapping by 
NMR spectroscopy. HSQC spectra of 15N-labelled 
RalB alone and in the presence of increasing 
amounts of unlabelled peptide were recorded 
(Figure 7A). Backbone amide peaks that shift 
position during the titration correspond to residues 
that are perturbed on peptide binding. Most of 
these will be within or proximal to the peptide 
binding site, although some can report on small 
conformational differences in the protein on 
peptide binding. The distances that each residue 
shifted are shown plotted in Figure 7B. During the 
titration, some peaks disappeared or moved too far 
to be reliably assigned and have been given an 
arbitrary value of 0.3 ppm. Residues whose shifts 
were perturbed were mapped onto RalB (Figure 
7C). These are clearly localized on one surface of 
the protein. Although not all the residues within 
the switch regions were visible in the free RalB 
spectra due to their conformational exchange, 
several surrounding residues are shifted, 
suggesting that the peptide is binding at the 
switches in accordance with previous data. 
Residues Tyr51 and Arg52, just C-terminal to 
switch 1, disappeared during the titration: these 
residues are therefore likely involved in peptide 
binding and have been shown previously to be 
involved in Ral interactions with effector proteins 
(35, 40). An overlay of the peptide binding site 
obtained by chemical shift mapping with known 
Ral-effector complexes suggests that there is a 
high degree of overlap with the effector binding 
interfaces (Figure 7D). 
 
Disruption of Ral-effector complexes in 
mammalian cell lysates 
 
Competition SPAs (Figure 6A and B) 
demonstrated that the optimized peptides were 
able to disrupt Ral effector complexes in vitro, 
however we also wanted to test the selectivity of 
the peptides for Ral in a complex cell mixture. We 
therefore examined whether the peptides could 
disrupt Ral-effector complexes in a mammalian 
cell lysate. HEK293T cells were transfected with 
V5-tagged, constitutively active (Q72L), RalB 
alone or with flag-tagged RLIP76. Peptides were 
incubated in the cell lysate at the concentrations 
indicated prior to RalB immunoprecipitation via 
its V5 tag. The presence of bound effector 
proteins, endogenous Sec5 and flag-tagged 
RLIP76, was assessed by western blotting (Figure 
8). The HLR-sol and L-sol peptides were able to 
inhibit the interactions between Ral and the 
effector proteins in a dose-dependent manner, 
while the negative control peptide with a W430A 
mutation did not inhibit complex formation.   
 
Assessment of peptide helicity by circular 
dichroism 
 
CD was used to assess the helicity of the original 
(SP1) peptide (34) and the second-generation 
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peptides with solubilizing mutations (Figure 9). 
All peptides had some helical character, as 
demonstrated by the double minima at 208 and 
222 nm. Addition of the solubilizing salt bridges 
to the wild-type peptide reduced the overall 
helicity to the same level as the unstapled control 
peptide. Similarly, the HLR-sol peptide with 
solubilizing salt bridges was less than 50% helical. 
The L-sol peptide was slightly more helical that 
the HLR-sol peptide, implying that replacement of 
Glu with His or Lys with Arg reduced the helicity 
of the HLR-sol peptide. The helical propensity of 
Glu is higher than that of His, while the propensity 
of Lys and Arg are similar (41), suggesting that it 
is the His substitution that affects helicity most. 
Nevertheless, the addition of two salt bridges, 
which replaced hydrophobic residues with charged 
sidechains, reduced the overall helicity compared 
to the original sequence. It is likely that the 
original hydrophobic residues could form 
hydrophobic interactions with multiple 
surrounding residues, which could stabilize a 
helical structure (42).  
 
Several studies have found that target affinity 
improves with increased peptide helicity (43, 44), 
raising the possibility that these peptides would 
have improved binding to Ral proteins if their 
helicity could be improved e.g. by altering the 
solubilizing residues, incorporation of alpha-
substituted amino acids or inclusion of a second 
staple.  
 
Contributions of residues in helix α1 of the 
RLIP76 RBD 
 
In the context of the RLIP76 RBD, which is ~ 
90% helical (Figure S3), the HLR and L sequences 
bind tightly to Ral proteins. It is known that within 
the α1 helix of the RLIP76 RBD, which is not 
present in the peptides, residues Leu409 and 
His413 are involved in the interaction with Ral 
proteins. When these residues were previously 
mutated individually to alanine in the RLIP76 
RBD, the binding to Ral proteins was significantly 
reduced (36). These key contacts were therefore 
both mutated to alanine, removing all binding 
contributions from the α1 helix within the RLIP76 
RBD coiled-coil but preserving the interactions of 
the α2 helix. The L409A/H413A mutations were 
also made in the context of the HLR 
(E427H/Q433L/K440R) RBD mutant and CD was 
used to assess the helicity and coiled-coil structure 
of the constructs (Figure 10A). Coiled-coil content 
can be estimated from CD data using the 
[θ]222/[θ]208 ratio, where [θ] is mean residue 
ellipticity at 222 and 208 nm respectively: coiled-
coils give values of approximately 1.0 while single 
α-helices give values closer to 0.8 (45, 46). The 
helicity was not affected by the introduction of the 
L409A/H413A mutations, and the [θ]222/[θ]208 
ratios confirmed that the coiled-coil content was 
also unaffected. The affinities of the 
L409A/H413A mutated RBD constructs for RalA 
were then measured by competition SPA (Figure 
10B). Comparison of the wild-type RBD and the 
L409A/H413A mutant showed that removal of the 
interactions made by Leu409 and His413 reduced 
the affinity ~125-fold. Similarly, with the HLR 
mutations present the affinity was reduced ~300-
fold, indicating that the contribution of the Leu409 






In this work, we successfully employed a CIS 
display maturation selection to identify sequence 
changes in the RLIP76 RBD that improve affinity 
for Ral proteins. In particular, the consensus 
sequence E427X/Q433L/K440R (Cluster 3, Figure 
1A), where X denotes a range of amino acids, 
produced sequences with the greatest 
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improvement in affinity for Ral proteins. The 
tightest binding sequences, termed HLR 
(E427H/Q433L/K440R) and SMLR 
(E427S/L429M/Q433L/K440R) displayed 
affinities of 5 and 3 nM for RalA, respectively, a 
vast improvement on the wild-type RBD affinity 
of around 100 nM. ITC revealed that the Q433L 
mutation was the key driver for improved affinity, 
resulting in a ~20-30 fold improvement in affinity 
compared to the wild-type RBD. Crystal structures 
of the HLR and SMLR mutant RBDs in complex 
with RalB revealed that this leucine side chain is 
able to sustain a network of hydrophobic 
interactions involving Ral and RBD residues. 
 
We sought to apply these changes to our lead 
stapled peptide based on the α2 helix (residues 
423-446) of the RLIP76 RBD (SP1), which we 
previously showed could bind to Ral proteins and 
inhibit RalB-mediated autophagy. However, 
further investigations into this peptide led us to 
uncover issues with non-specific binding, 
confounding binding data generated previously. 
The lead peptide, SP1, was relatively hydrophobic 
and poorly soluble, therefore we sought to 
improve the solubility of the peptides by addition 
of salt bridges that could stabilize their helical 
structure. The addition of two salt bridges 
replacing hydrophobic residues on the back face of 
the peptide resulted in soluble peptides that no 
longer bound non-specifically to other GTPases. 
The measured affinity of the soluble template (wt-
sol, Kd RalA ≈ 50 μM) was however much weaker 
than our previous lead peptide, suggesting that the 
Kd of the lead peptide was at least partly a result of 
non-specific effects, as equal and even greater 
affinities were measured for other small GTPases. 
Additionally, the SP1 lead peptide displayed an 
apparent Kd for RalB that was 5-fold tighter than 
for RalA, despite the RLIP76 RBD having the 
same affinity for both Ral proteins. This suggests 
that the SP1 peptide either bound at a site differing 
from the RLIP76 RBD binding regions, that are 
identical between RalA and RalB, or was able to 
contact an additional site on RalB. 
Recently, it has been found that several highly-
cited peptides suffer similar issues with non-
specific binding, including the hydrocarbon-
stapled peptide targeting the K-Ras/SOS1 
interaction (SAH-SOS1A), identified by Walensky 
and colleagues (47, 48). FP assays were shown to 
be particularly susceptible to these misleading 
results, with non-specific binding observed for a 
range of non-target proteins and to plate surfaces, 
demonstrating the importance of validating 
peptide binding through orthogonal assays. We 
established that the non-specific binding of our 
SP1 peptide in FP assays was due to a 
hydrophobic patch on the back face of the peptide, 
comprising residues that would normally be 
embedded in the coiled-coil interface and 
exacerbated by the hydrocarbon staple. Our 
findings join other examples demonstrating that 
care must be taken when using peptide sequences 
that are not normally solvent-exposed in the parent 
protein structure. However, we also demonstrate 
here that careful modifications, such as the 
introduction of charged residues can resolve these 
issues, when the problematic regions are identified 
through the analysis of known structures. 
 
When the sequence substitutions identified by CIS 
display were included in the soluble peptide 
template to produce the HLR-sol and L-sol 
peptides, the affinity improved to a similar extent 
as in the RLIP76 RBD. Both peptides bound with 
a Kd of 3 μM measured by competition SPA, an 
improvement of around 16-fold compared to the 
wild-type template, while the same substitutions in 
the RBD (HLR mutant) improved affinity ~20-
fold. The optimized peptides were selective for the 
active form of Ral proteins, with minimal binding 
observed for the GDP-bound form and were 
highly selective for Ral proteins over a panel of 
Stapled peptides targeting the Ral GTPases 
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small GTPases. NMR titrations of the HLR-sol 
peptides also confirmed that the peptide was 
bound at the effector binding surface on RalB, 
while the competition SPA and co-
immunoprecipitation experiments revealed that the 
peptides were competitive with binding of 
multiple Ral effectors, RLIP76 and Sec5.  
 
We also attempted to assess whether the peptide 
could disrupt RalB/Exo84 complex formation in 
co-immunoprecipitation experiments, however no 
validated commercial Exo84 antibodies were 
compatible with this methodology. Jin et al. have 
previously identified the RalA residues involved in 
binding to Exo84 (40) and in fact all of these 
residues that were observable in our NMR 
mapping experiments. Lys16, Tyr36, Arg52, 
Asp65, Ile78 and Asn81, experienced significant 
chemical shift perturbations on titration of the 
peptide, HLR-sol, into 15N-labelled RalB (Figure 
7B). This suggests that the HLR-sol peptide is 
utilizing many of the same residues as Exo84 for 
binding and is therefore likely to also compete 
with this effector protein. There are also likely to 
be more shared residues in the switch regions that 
were missing from our NMR spectra due to their 
conformational flexibility.  
 
Inclusion of the salt bridges to improve solubility 
lowered the helical content of the peptides, 
presumably due to disruption of a hydrophobic 
network of interactions on the back face of the 
peptide. To assess whether the lower helicity was 
impacting the binding affinity, a model RLIP76 
RBD construct in which the binding contacts in 
the α1 helix were removed (L409A/H413A, Figure 
11) was used to estimate the maximal affinity of a 
peptide sequence based on the α2 helix alone. 
Assuming that Leu409 and His413 are the only 
significant contact points on helix 1, the HLR 
L409A/H413A variant RLIP76 RBD is a mimic 
for an HLR peptide with a stabilized helix. It is 
therefore informative to compare the Kd of the 
HLR L409A/H413A RBD (1.5 μM) with that of 
the HLR-sol stapled peptide (3 μM, Figure 6A). 
These data suggest that increasing the helicity of 
the peptide would only improve affinity for Ral 
proteins by around 2-fold, therefore no further 
attempts to improve peptide helicity were made. 
Predictably, it is likely that Leu409 and His413 
make the crucial contacts that contribute to the 
increased affinity of the RBD over the peptides. 
 
To improve the affinity of the peptides, the 
sequence could be extended in order to include the 
critical binding contacts in the α1 helix, Leu409 
and His413. To this end, it would be highly 
desirable to have a reliable method to stabilize 
coiled-coil peptides in addition to single helices, 
especially given that a large number of 
GTPase/effector interactions are mediated by a 
pair of helices (49). Arora and colleagues have 
made some progress in this area by incorporating a 
chemical linker to bridge two helices that could 
stabilize a coiled-coil structure of the peptides (50, 
51).  
 
Previously, we observed that our lead peptide 
(SP1) was able to enter cells, using confocal 
microscopy to confirm the presence of FAM-
labelled peptide inside the cells (34). 
Unfortunately, the modifications made to the 
peptide to improve affinity and solubility meant 
that the peptides were no longer able to enter cells 
(data not shown), therefore their activity in cell 
culture could not be assessed. It has been shown 
previously that stapled peptides need to form an 
amphipathic helix in order to enter cells (52) and 
the amphipathicity of our peptide was disrupted by 
the inclusion of the solubilizing salt bridges. 
Amphipathicity versus solubility is likely to be a 
challenge when designing stapled peptides, 
however a cell-penetrating peptide (CPP) 
sequence could be used to facilitate cell entry. 
Stapled peptides targeting the Ral GTPases 
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Like Ras proteins, the Ral GTPases are 
challenging drug targets and there are currently no 
well-validated Ral inhibitors that can be used to 
study Ral activity or to be used as a treatment for 
Ras-mutant cancers. The Theodorescu group 
previously identified a small molecule inhibitor 
that stabilized the inactive, GDP-bound form of 
Ral proteins through binding an allosteric site (29). 
This molecule was able to inhibit Ral activation 
and inhibited tumour growth in a mouse model of 
lung cancer. However independent investigations 
comparing the effects of the inhibitor to Ral 
knockdown with siRNA showed that the inhibitor 
caused off-target effects in platelets (53). The 
covalent inhibitors that have been developed for 
K-Ras G12C offer great promise for the direct 
inhibition of this Ras mutant, however most Ras 
mutants found in cancer, like the Ral proteins, lack 
an accessible cysteine that can be exploited for 
inhibition. However, Bum-Erdene et al. have very 
recently demonstrated that Tyr82 of Ral, located 
within the effector binding site, can be modified 
by aryl sulphonyl electrophiles (30). The 
compounds they developed are currently not 
suitable for animal trials due to their low affinity 
and poor serum stability but this work 
demonstrates a novel approach to target the Ral 
GTPases that could be incorporated to improve 
our peptide inhibitors. In the wild-type RLIP76 
RBD/RalB complex, His413 of the RBD forms a 
hydrogen bond with Tyr82 of Ral (Figure 11). In 
our peptides His413 is not included in the 
sequence, therefore the hydroxyl group of Tyr82 is 
presumably not involved in the peptide interaction 
but remains proximal to the binding site. This 
therefore offers an enticing opportunity to convert 
stapled peptides into covalent inhibitors targeting 
Ral proteins, as a reactive warhead could be 
installed on the side of the peptide directed 
towards Tyr82. Covalent inhibitors require a lower 
binding affinity for sustained inhibition due to 
irreversible modification of the target. As our 
peptides display excellent selectivity for the Ral 
proteins, they could be highly effective as covalent 
inhibitors with limited off-target effects. 
 
The peptides could also form the basis for 
proteolysis targeting chimeras (PROTACs), 
molecules designed to target a protein for 
degradation: this catalytic mechanism requires a 
lower target affinity than is needed for sustained 
inhibition. Degradation of Ral proteins offers an 
interesting opportunity for the inhibition of 
oncogenic Ras signalling, as several Ras-mutant 
cancers require Ral activity for survival, unlike 
non-transformed cells (24). 
 
In conclusion, the second-generation peptides we 
have produced demonstrate far superior selectivity 
for Ral proteins and improved physical properties 
compared to our previous lead peptide. With the 
potential for further modifications to aid their 
activity, they represent a further advance towards 







Proteins were expressed from pGEX vectors 
(Cytiva) as GST fusion proteins or from pMAT10 
(35) as His6-MBP fusion proteins. The constructs 
expressing RalA (pMAT10, residues 1-184, 
Q72L) (36), RalB (pMAT10, 1-185, Q72L) (36), 
RLIP76 RBD (pGEX-HisP, 393-446, C411S) (54), 
RhoA (pGEX-2T, 1-186, F25N/Q63L) (55), Rac1 
(pGEX-2T, 1-185, Q61L) (56), Cdc42 (pGEX-2T, 
1-184, Q61L) (56) and K-Ras (pGEX-6P, 1-169) 
(38) were prepared, expressed and cleaved from 
their tags as described previously. 15N-labeled 
RalB (1-185, Q72L) was prepared from pET16b in 
M9 minimal media supplemented with 15NH4Cl as 
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Ral proteins were labeled with [3H]GTP for use in 
SPAs as follows. [3H]GTP (0.15 mCi, 
PerkinElmer Life Sciences) was dried by 
centrifugal evaporation. Ral (0.7 mg) and 0.3 M 
(NH4)2SO4 were added in 140 μL of buffer (10 
mM Tris-HCl, 150 mM NaCl, 1 mM DTT, pH 
7.5). The mixture was incubated at 37 °C for 3 h 
and unbound nucleotide was removed with 
Sephadex G25 spin columns (GE Healthcare). 
Small GTPases were exchanged for GMPPNP as 




The peptide sequences encoding the RLIP76 RBD 
(residues 423-446, C411S) were used in a CIS 
display affinity maturation selection.  Construct 
preparation, biopanning reactions, next generation 
sequencing and output ranking were purchased 
from Isogenica (Chesterford Research Park, Essex, 
UK). Biotinylated RalA·GMPPNP and 
RalB·GMPPNP were produced by incubating 1 
mg of each protein with a 20X excess of biotin in 
amine free buffer at room temperature for 30 min. 
Labelled protein was separated  using a PD10 
buffer exchange column following manufacturers 
instructions. During the selection, certain residues 
were restricted to a subset of sidechains: Leu423 
and Ala438 were allowed to change to Asp, Glu, 
Lys, Asn, Arg, Ser, Ala, Gly and Thr, while 
Arg444 was restricted to His, Asn, Ser, Lys, Gln, 
and Arg. Substitution by any of the 20 amino acids 





Scintillation proximity assays (SPAs)  
 
Direct binding SPAs –RLIP76 RBD-His variants 
(80 nM) were immobilized on Protein A SPA 
fluoromicrospheres (Perkin Elmer) via an anti-His 
antibody (H1029, Sigma-Aldrich) in 50 mM Tris-
HCl pH 7.5, 2 mM DTT, 1 mM MgCl2 and 0.2 
mg/mL BSA. [3H]GTP·Ral proteins were titrated 
in at the concentrations indicated in the results. 
Experiments were performed as described 
previously (36). The equilibrium binding constants 
(Kd) for the effector-Ral interactions were 
determined by monitoring the SPA signal in the 
presence of varying concentrations of 
[3H]GTP·Ral and fitted using nonlinear regression 
with the computer program Grafit. 
Competition SPAs – Reaction mixtures were set up 
as described for direct measurements with the 
addition of [3H]GTP·RalA (100 nM) or 
[3H]GTP·RalB (250 nM). The effect of 
competition was assessed by measuring the SPA 
signal in the presence of increasing concentrations 
of peptides or proteins at the concentrations 
indicated in the results. The data were fitted to an 
appropriate binding isotherm as described 
previously (58).  
 
Circular dichroism (CD) 
 
CD spectra were recorded at 1 nm intervals 
between 260 and 185 nm using an Aviv Model 
410 CD spectrometer with a 1 mm path length 
quartz cuvette at 298 K. Three scans were 
recorded for each peptide or protein, the data were 
averaged and the buffer background was 
subtracted. RLIP76 RBDs were measured at 0.2 
mg/mL in 10 mM phosphate buffer pH 7.3 and 
150 mM NaF, while peptides were measured at 0.2 
mg/mL in water. The helical content of each 
peptide and RBD was determined using the 
CDSSTR method with reference Set 3 and 
DichroWeb (59–61). 




Complexes of RalB·GMPPNP and RLIP76 RBD 
(HLR and SMLR mutants) were generated by 
incubating RalB·GMPPNP in the presence of 
excess RLIP76 RBD prior to purification on an 
S75 gel filtration column (GE Healthcare) in 20 
mM Tris-HCl, pH 7.5, 100 mM NaCl and 1 mM 
MgCl2. 
Co-crystals of RalB·GMPPNP and RLIP76 RBD 
(HLR and SMLR mutants) were generated by 
screening the co-purified complexes at 10 mg/mL 
with the pHClear Suite I screen (Qiagen). 
Crystallization trials were set up using the 
Mosquito robotics system (SPT Labtech). Drops 
were set up with 0.2 μL protein solution and 0.2 
μL screen solution using the sitting drop vapour-
diffusion method. Crystals formed in the condition 
containing 0.1 M Bicine, pH 9.0, 30% w/v 
polyethylene glycol 6000 at 20°C. The crystals 
were frozen in liquid nitrogen prior to data 
collection. X-ray diffraction data was collected at 
the Diamond Light Source on beamlines IO3 and 
IO4 and processed using the pipedream package 
(Global Phasing Ltd). The structures were 
determined by molecular replacement using 
Phaser (62) from the CCP4 package (63) and were 
iteratively built and refined using Coot (64) and 
PHENIX (65). Co-ordinates have been deposited 
to the protein data bank under the accession codes 
6ZQT (HLR mutant) and 6ZRN (SMLR mutant).  
 
Isothermal titration calorimetry (ITC)  
 
ITC data were collected using a MicroCal iTC200 
calorimeter at 298 K in 50 mM Tris-HCl, pH 7.5, 
150 mM NaCl, 1 mM MgCl2. RalB (40 - 200 μM, 
8-10x cell concentration) was titrated into RLIP76 
RBD variants (5-20 μM) in 19 x 2 μL additions 
with 120 s between injections. Control 
experiments were performed by titrating RalB 
(200 μM) into buffer. Data were fitted using 





Peptides with an amidated C-terminus were 
synthesized by standard Fmoc/tBu solid-phase 
chemistry on an automated peptide synthesizer 
(PTI Prelude) using Rink Amide MBHA resin 
(0.30 mmol/g loading, 500 mg, 0.15 mmol scale). 
Fmoc-(S)-pentenylalanine required for staple 
formation was manually coupled as follows. 
Fmoc-(S)-pentenylalanine (228 mg, 0.6 mmol, 4 
eq), hexafluorophosphate azabenzotriazole 
tetramethyl uranium (HATU, 228 mg, 0.6 mmol, 4 
eq) and N,N-diisopropylethylamine (DIPEA, 210 
μL, 1.2 mM, 8 eq) were added to the deprotected 
resin in N,N-dimethylformamide (DMF, 5 mL) 
and incubated with shaking at room temperature 
for 1 h. The olefin hydrocarbon substituted 
peptides were chemically stapled by metathesis 
reaction with 2 x 5 mL Grubbs’ first generation 
catalyst (6 mM) in 1,2-dichloroethane at room 
temperature for 2 h with N2 sparging (66). FAM-
labelling was carried out using 5-
carboxyfluorescein (282 mg, 0.75 mmol, 5 eq), 
Hydroxybenzotriazole (HOBt, 230 mg, 1.5 mmol, 
10 eq) and N,N'-Diisopropylcarbodiimide (DIC, 
237 μL, 1.5 mmol, 10 eq) in DMF (5 mL). 
Reaction vessels were covered in foil and 
incubated with shaking at room temperature for at 
least 24 h. Peptide resins were washed extensively 
with dichloromethane, DMF and diethyl ether and 
dried before cleaving from the resin with 89% 
trifluoroacetic acid (TFA), 5% triisopropylsilane 
(TIPS), 1.5% ethanedithiol (EDT), 1.5% water, 
1.5% thioanisole and 1.5% phenol for 4 h at room 
temperature. Peptides were purified by reversed-
phase preparative HPLC (Waters X-Bridge, 19 x 
250 mm, C18 OBD) and analyzed by LC/MS 
(Agilent Polaris C8A, 2.1 x 50 mm); both systems 
eluting gradients of acetonitrile (0.1% v/v TFA) 
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against water (0.1% v/v TFA). See Table S2 for 
characterization data for all peptides synthesized. 
The peptides termed SP1, non-stapled and HLR-
SP1 were purchased from Eurogentec. 
 
Fluorescence polarization (FP) 
 
FP experiments were performed on a BMG 
Labtech Pherastar fluorimeter at 298 K with 
excitation at 485 nm and emission at 520 nm as 
described previously (34), using 20 nM FAM-
labelled peptide. Plates were read after 30 min 
incubation at room temperature. Data were fitted 
to a single-site binding model using non-linear 
regression analysis in GraphPad prism 8.4 to 
obtain Kd values and their standard errors. 
 
1H,15N HSQC NMR Spectroscopy 
 
Experiments were recorded on a Bruker AV800 at 
298 K using 100 μM 15N-labeled RalB·GMPPNP 
in 50mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM 
MgCl2, 10% D2O. For the titration experiments, 
0.25, 0.5, 1.0, 1.25 and 2.0 equivalents of HLR-sol 
were added to the protein solution and spectra 
recorded after each peptide addition. Chemical 
shift perturbations (δ) were calculated using the 
following equation; 𝛿 = 	%𝛿&'( + (0.15𝛿&/0), 
where δ1H and δ15N are the chemical shift changes 
for the 1H and 15N dimensions, respectively. NMR 
data were processed using the AZARA package 
(Wayne Boucher, University of Cambridge) and 




3 x 106 HEK293T cells were seeded in 10 cm 
dishes 48 h before the end point, in DMEM 
supplemented with 10% FBS. For RalB/RLIP76 
co-immunoprecipitations cells were transfected 
with GFP (1 μg), flag-RLIP76 (5 μg) and V5-RalB 
Q72L (5 μg) or GFP only (11 μg) 24 h before the 
endpoint, while for RalB/Sec5 co-
immunoprecipitations cells were transfected with 
GFP (1 μg) and V5-RalB Q72L (5 μg) or GFP 
only (6 μg) 24 h before the endpoint. Dishes were 
lysed in 1 mL lysis buffer (50 mM Tris-HCl pH 
7.8, 150 mM NaCl, 1% Triton, 1 mM EDTA, 1 
mM sodium orthovanadate, 1 mM β-
glycerophosphate and protease inhibitor cocktail 
(Sigma-Aldrich). Lysates (1 mL) were centrifuged 
at 17,000 g for 20 min and added to Protein G 
Dynabeads (30 μL, Invitrogen) pre-incubated with 
anti-V5 antibody (1 μg, R960-25, Invitrogen). 
Peptides, at the concentrations indicated in the 
results, were added and incubated with rotation for 
1 h at 4°C. Precipitated complexes were washed 
with lysis buffer (3 x 500 μL). Samples were 
resolved by SDS-PAGE and transferred to PVDF 
membranes (Immobilon-P). Membranes were 
probed by immunoblotting with the following 
primary antibodies: anti-V5-HRP (R961-25, 
Invitrogen), anti-flag-HRP (A8592, Sigma-
Aldrich) and anti-Sec5 (EPR9420, Abcam).  
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96 ± 17 109 ± 16 
HLR ....H.....L......R...... 5 ± 3 1 ± 2 
SMLR ....S.M...L......R...... 3 ± 3 2 ± 2 
DVLR ....D.V...L......R...... 12 ± 4 7 ± 2 
WDASQSR ...WD.A...SQ..S..R...... 3020 ± 720 6970 ± 930 
WNASELR ...WN.A...SE..L..R...... 2750 ± 850 10350 ± 2250 
WDASTAY ...WD.A...ST..A..Y...... 530 ± 70 1200 ± 140 
a Standard error from curve fitting.  
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Table 2: Data Collection and Refinement Statistics for RalB·GMPPNP in complex with the RLIP76 RBD 





PDB identifier 6ZQT 6ZRN 
Resolution (Å) 50.4-1.51 (1.55-1.51) 65.8-1.48 (1.56-1.48) 
Space group P 1 21 1 P 1 21 1 
Cell dimensions 
 a,b,c (Å) 
α,β,γ (°) 
 
47.5, 77.4, 66.4  
90, 90.3, 90 
 
47.2, 77.5, 65.8 
90, 90.1, 90 
Total reflections 569,182 (24,662) 1,159,648 (176,059) 
Redundancy 7.6 (4.5) 14.8 (15.4) 
Completeness (%) 99.7 (98.7) 100.0 (100.0) 
I/σ 18.3 (1.2) 8.0 (1.3) 
Wilson B-factor (Å2) 24.5 19.3 
Refinement  
Rwork/Rfree (%) 18.9/22.1 (33.6/36.3) 20.1/23.9 (34.9/36.1) 
No. of protein atoms 3686 3725 
  No. of ligand atoms 72 78 
  No. of water molecules 362 244 
RMSD bond length (Å) 0.005 0.006 
RMSD bond angles (°) 0.75 0.80 
Ramachandran statistics  
In favoured regions (%) 










Mean B-factor (Å2) 34.5 30.8 
a The numbers in parentheses represent values for the highest resolution shell. 
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Table 3: Binding parameters obtained from ITC for RLIP76 RBDs titrated into RalB. 






LSKEERLWEVQRILTALKRKLREA 2720 ± 640 1.00 ± 0.01 -10.5 ± 0.2 
-2.89 ± 
0.33 
HLR ....H.....L......R...... 96.2 ± 29.1 0.89 ± 0.12 -17.7 ± 2.9 -8.12 ± 3.08 
LR ..........L......R...... 132 ± 46 0.81 ± 0.00 -21.0 ± 1.3 -11.6 ± 1.5 
HL ....H.....L............. 224 ± 94 0.83 ± 0.15 -19.5 ± 2.3 -10.3 ± 2.0 
HR ....H............R...... 4350 ± 630 0.99 ± 0.06 -9.05 ± 0.16 
-1.72 ± 
0.08 
L ..........L............. 110 ± 19 0.75 ± 0.06 -22.4 ± 1.4 -12.9 ± 1.3 
a Data reported are the mean values from two independent experiments ± one standard deviation. 
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Table 4: Affinity measurements for second-generation peptides binding to a panel of small GTPases. 
GTPase Assay Kd (μM)
a 
HLR-sol L-sol 
RalA·GTP Competition SPA (RLIP76)
 2.97 ± 0.29 3.09 ± 0.32 
Competition SPA (Sec5) 1.74 ± 0.15 1.81 ± 0.14 




RalB·GMPPNP 21.1 ± 1.8 24.4 ± 5.0 
K-Ras·GMPPNP NB NB 
RhoA·GMPPNP NB NB 
Rac1·GMPPNP NB NB 
  wt-sol W430A-sol 
RalA·GTP Competition SPA (RLIP76) 48.6 ± 7.7 > 100 
a Standard errors from curve fitting. NB - no binding.  





Figure 1. CIS display maturation of the RLIP76 RBD. A. Schematic of CIS display (37). The CIS 
display constructs comprised the RLIP76 RBD library fused to the gene encoding RepA. The positions 
that were allowed to alter during the selection are shown as orange Xs. B. Structure of RalB in complex 
with the RLIP76 RBD (393-446, PDB ID: 2KWI). Residues of the RLIP76 RBD that were allowed to 
alter during the CIS display selections are shown as orange sticks: all of these residues were located 
within the α2 helix and were proximal to the Ral-binding interface. Trp430 is shown as blue sticks and 
was retained during all selections as it is known to be critical for binding to Ral proteins. C. Sequence 
clusters identified with the highest frequencies in the selections. The residue positions in the RLIP76 
RBD are listed. ‘-’ denotes no sequence change and ‘X’ denotes that a variety of amino acids were found 
at the position.  
 
Figure 2. In vitro validation of CIS display hits. Affinities were measured by competition SPAs. 
Mutant RBDs at the concentrations indicated were titrated into fixed concentrations of [3H]-GTP RalA 
(A) or [3H]-GTP RalB (B) and His-tagged RLIP76 RBD (wild-type) immobilized on SPA beads. Results 
from two independent experiments are shown and data were fitted to the average result. Data and fits are 
displayed as a percentage of the maximum SPA signal measured for each condition. Data were fitted to a 
competitive binding isotherm describing a pure competition model to give apparent Kd (Ki) values for the 
peptides as described previously (58).  
 
Figure 3. Structures of the HLR and SMLR mutant RBDs in complex with RalB. A. An overlay of 
the structures of the HLR mutant (orange, PDB ID: 6ZQT) and SMLR mutant (red, PDB ID: 6ZRN) 
RLIP76 RBDs in complex with RalB·GMPPNP. B. Zoomed views of the wild-type RBD/RalB complex 
(left three panels, PDB ID: 2KWI) and the HLR-mutant RBD complex (right three panels, PDB ID: 
6ZQT), showing the interactions made by mutated residues. RalB is shown in blue, while the RLIP76 
RBD is shown in orange.  
 
Figure 4. Dissecting improved binding of the HLR mutant RBD to RalB. Representative data from 
ITC experiments are shown for titrations of RalB·GMPPNP into the indicated RLIP76 RBD constructs. 
The parameters for the fit for these individual experiments are shown in each panel. For the average 
parameters obtained from two experiments, see Table 3. (A) wild-type RLIP76 RBD, (B) HLR, (C) LR, 
(D) HL, (E) HR, (F) L mutant. 
 
Figure 5. Improving the solubility profile of stapled peptides based on RLIP76. A. The RLIP76 RBD 
structure (PDB ID: 2KWI) shows that the RLIP76 RBD coiled-coil is held together by hydrophobic 
residues at the helix interface (shown as orange sticks). B. Modifications made to the lead stapled peptide 
(SP1) to improve solubility and stabilize the helical structure. Residues shaded orange in the SP1 
sequence match those coloured orange in the α2 helix in A. C. Soluble peptide sequences were produced 
synthetically. Solubilizing salt bridges are shown in blue, and sequence changes from the ‘wild-type’ (wt-
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sol) sequence are highlighted in green boxes. X = position of stapled residues, FAM = 5-
carboxyfluorescein, PEG = polyethylene glycol linker, amino-4,7-dioxanonanoic acid. 
 
Figure 6. Binding of soluble peptides to Rals and related small GTPases. A. Peptides at the 
concentrations indicated were titrated into fixed concentrations of [3H]-GTP RalA and His-tagged 
RLIP76 RBD (wild-type) immobilized on SPA beads. Data and fits were produced as described for 
Figure 2. Kd = HLR-sol, 2.97 ± 0.29 μM; L-sol, 3.09 ± 0.32 μM; wt-sol, 48.6 ± 7.7 μM; W430A-sol, > 
100 μM. B. Peptides and the RLIP76 RBD at the concentrations indicated were titrated into fixed 
concentrations of [3H]-GTP RalA and GST-tagged Sec5 RBD immobilized on SPA beads. Data and fits 
were produced as described for Figure 2: Kd = RLIP76 RBD, 115 ± 30 nM; HLR-sol, 1.74 ± 0.15 μM; L-
sol, 1.81 ± 0.14 μM C + D. FP data for direct binding of 20 nM FAM-labelled HLR-sol (C) and L-sol (D) 
to varying concentrations of indicated GMPPNP-bound small GTPases. n = 3, except for K-Ras where n 
= 2. HLR-sol: Kd = 16.6 ± 1.3 μM, RalA; 21.1 ± 1.8 μM, RalB. L-sol: Kd = 19.8 ± 3.9 μM, RalA; 24.4 ± 
5.0 μM, RalB. No Kd values could be estimated for K-Ras, RhoA or Rac1 as binding was too weak. E + 
F. FP data for direct binding of 20 nM FAM-labelled HLR-sol (E) and L-sol (F) to varying 
concentrations of RalA·GMPPNP and RalA·GDP. Kd values for RalA·GMPPNP are as in D + E. No Kd 
values could be estimated for RalA·GDP as binding was too weak. n =3. 
 
Figure 7. Titration of HLR-sol into 15N-labelled RalB. A. HSQC spectra of 15N-labelled RalB alone 
(red) and after the addition of 2 equivalents of HLR-sol peptide (blue). B. Chemical shift perturbation for 
backbone amides of RalB after addition of 2 equivalents of HLR-sol peptide. Peaks that have shifted too 
far to be reliably assigned have been given a chemical shift perturbation of 0.3 ppm and are shown in 
grey. Some switch region residues are missing from the free RalB spectrum due to their conformational 
flexibility, therefore shift distances cannot be assigned and no bar is shown. The average shift change 
(0.06) and the average plus one standard deviation (0.13) are marked by dotted lines. The location of 
switch I residues (SWI, 41-51) are indicated in blue and switch II residues (SWII, 69-81) are indicated in 
magenta. Shifts marked with a star (*) indicate those that are involved in binding to Exo84 that shift on 
peptide binding. C. Residues with the largest chemical shift distances mapped onto the surface of RalB 
(PDB: 2KWI). Shifts greater than 0.13 ppm are coloured red and those greater than 0.06 ppm are coloured 
orange. Switch I residues are coloured blue and switch II residues are coloured magenta. D. Structures of 
Ral with RLIP76 RBD (cyan, PDB ID: 2KWI), Exo84 RBD (yellow, PDB ID: 1ZC3) and Sec5 RBD 
(purple, PDB ID: 1UAD), with RalB coloured as in C.  
 
Figure 8. Disruption of Ral-effector complexes by second-generation stapled peptides in a 
mammalian cell lysate. A-C. The indicated concentrations of HLR-sol (A), L-sol (B) and W430A-sol 
(C) stapled peptides were added to HEK293T cell lysates transfected with GFP only or V5-tagged RalB 
Q72L and flag-tagged RLIP76 24 h prior to lysis. Beads coated with an anti-V5 antibody were added to 
the lysate mixture to precipitate RalB and any bound proteins. The presence of RalB and bound RLIP76 
was assessed by probing with anti-flag (RLIP76) and anti-V5 (RalB). WCL – whole cell lysate. D-F. Co-
immunoprecipitations were performed without RLIP76-flag transfection as above in the presence of 
increasing concentrations HLR-sol (D), L-sol (E) and W430A-sol (F) stapled peptides. The presence of 
RalB and bound Sec5 was assessed by probing with anti-Sec5 and anti-V5 (RalB). 
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Figure 9. CD spectra of stapled peptides. CD spectra of the peptides were measured over the 
wavelengths 185-260 nm with a peptide concentration of 0.2 mg/mL. The reported helicity (%) was 
estimated by the CDSSTR method and reference set 3 using Dichroweb (59–61). Residues forming the 
staple are shown as red Xs, solubilizing mutations are shown in blue and residues varying from the wt-sol 
template in HLR-sol and L-sol are shown in green squares.  
 
Figure 10. Binding of RLIP76 RBDs with key α1 helix residues mutated to alanine. A. CD spectra of 
the wild-type RLIP76 RBD and L409A/H413A RBD mutants were measured over the wavelengths 185-
260 nm with a protein concentration of 0.2 mg/mL. The calculated helicities and ratios of the mean 
residue ellipticities (θ) at 222 and 208 nm ([θ]222/[θ]208) are shown in the inset. B. Binding of the 
L409A/H413A mutant RBDs to RalA were measured by competition SPA. RBDs at the indicated 
concentrations were titrated into a fixed concentration of [3H]-GTP·RalA and His-tagged wild-type 
RLIP76 RBD immobilized on SPA beads. Data and fits were produced as described for Figure 2: Kd = 
wild-type, 128 ± 10 nM; L409A/H413A, 16.1 ± 3.1 μM; HLR, 5 ± 3 nM; HLR L409A/H413A, 1.50 ± 
0.17 μM.  
 
Figure 11. RLIP76 RBD helix 1 contacts. The NMR structure of RalB·GMPPNP in complex with the 
RLIP76 RBD (PDB ID: 2KWI) is shown, with RalB coloured blue and the RLIP76 RBD coloured grey. 
Residues within the RLIP76 RBD that, upon mutation to alanine, reduce binding to Ral more than 10-fold 
are shown in sticks and coloured in orange (36). In the α1 helix, these residues are Leu409 and His413. 
Tyr82 on Ral that has been exploited for covalent inhibition is shown as sticks and forms a hydrogen 
bond with His413 of the RLIP76 RBD. 
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